JAMES CREEK: Open Payments
NPI 1619091998 · CALEXICO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$413 in 19 payments from 9 companies in 2025. Trend: 2023 $464 · 2024 $401 · 2025 $413
Food & beverage: $413
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $173 |
| Corcept Therapeutics | 5 | $79 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| ABBVIE INC. | 2 | $28 |
| Ascensia Diabetes Care Us Inc. | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
Products named: Ozempic, Korlym, RECORLEV, GEMTESA, TRELEGY ELLIPTA, FARXIGA, VRAYLAR, CREON.
Industry payments across CA — which companies pay providers there.
